{"nctId":"NCT00884273","briefTitle":"Investigation of the Effect of Degarelix in Terms of Prostate Volume Reduction in Prostate Cancer Patients","startDateStruct":{"date":"2009-08"},"conditions":["Prostate Cancer"],"count":182,"armGroups":[{"label":"Degarelix 240 mg/80 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Degarelix"]},{"label":"Goserelin (3.6 mg) + bicalutamide (50 mg)","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Goserelin","Drug: Bicalutamide"]}],"interventions":[{"name":"Degarelix","otherNames":["FE200486","FIRMAGON"]},{"name":"Goserelin","otherNames":["ZOLADEX"]},{"name":"Bicalutamide","otherNames":["CASODEX"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Patient has given written informed consent\n2. Patient is 18 years or older\n3. Patient has histologically confirmed prostate cancer\n4. Patient has a serum prostate-specific antigen (PSA) level at screening \\>2 ng/mL\n5. The prostate size is \\>30 cubic centimetres (cc), measured by TRUS\n6. Patient has had a bone-scan within 12 weeks before inclusion\n7. Patient must be able to undergo transrectal examinations\n8. Patient has an estimated life expectancy of at least 12 months\n\nExclusion Criteria:\n\n1. Any previous treatments for prostate cancer\n2. Previous trans-urethral resection of the prostate (TURP)\n3. Is not considered a candidate for medical castration\n4. Use of urethral catheter\n5. Is currently treated with a 5-alpha reductase inhibitor\n6. Is currently treated with an alpha-adrenoceptor antagonist\n7. Treatment with botulinum toxin A (Botox)\n8. Require radiotherapy during the trial\n9. History of severe untreated asthma, anaphylactic reactions, or severe urticaria and/or angioedema\n10. Hypersensitivity towards any component of the investigational products or excipients\n11. Previous history or presence of another malignancy\n12. A clinically significant disorder\n13. A corrected QT interval over 450 msec\n14. Mental incapacity or language barrier precluding adequate understanding or co-operation\n15. Receipt of an investigational drug within the last 28 days proceeding screening\n16. Previous participation in any degarelix trial","healthyVolunteers":false,"sex":"MALE","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline in Prostate Size Based on Trans Rectal Ultra Sound (TRUS) at Week 12 (Full Analysis Set)","description":"TRUS is a method of measuring the size of the prostate.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-37.2","spread":"16.8"},{"groupId":"OG001","value":"-39.0","spread":"17.7"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Prostate Size Based on TRUS at Week 4 and 8","description":"TRUS is a method of measuring the size of the prostate.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-19.2","spread":"15.2"},{"groupId":"OG001","value":"-21.2","spread":"17.7"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-33.1","spread":"14.8"},{"groupId":"OG001","value":"-33.2","spread":"20.6"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Total International Prostate Symptom Score (IPSS) at Week 4, 8, and 12","description":"The IPSS is a tool commonly used to assess the severity of lower urinary tract symptoms (LUTS), and to monitor the progress of the disease once treatment has been initiated. The participant completes a questionnaire containing 7 questions regarding incomplete emptying, frequency, intermittency, urgency, weak stream, straining, and nocturia. Each question is assigned a score of 0-5. The total score is then classified according to the following scale: 0 to 7 = mildly symptomatic; 8 to 19 = moderately symptomatic; and 20 to 35 = severely symptomatic.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.09","spread":"4.36"},{"groupId":"OG001","value":"-1.36","spread":"5.86"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.55","spread":"5.95"},{"groupId":"OG001","value":"-3.13","spread":"6.06"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.39","spread":"6.66"},{"groupId":"OG001","value":"-2.74","spread":"6.37"}]}]}]},{"type":"SECONDARY","title":"Change in Serum Testosterone Levels During the Study","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.91","spread":null},{"groupId":"OG001","value":"-4.17","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.97","spread":null},{"groupId":"OG001","value":"-4.24","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.09","spread":null},{"groupId":"OG001","value":"-4.23","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Serum Prostate-Specific Antigen (PSA) Levels During the Study","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-20.25","spread":null},{"groupId":"OG001","value":"-12.10","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-22.5","spread":null},{"groupId":"OG001","value":"-14.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-25.15","spread":null},{"groupId":"OG001","value":"-13.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Quality of Life (QoL) Related to Urinary Symptoms at Each Visit","description":"The IPSS questionnaire included an additional single question to assess the participant's QoL in relation to his urinary symptoms. The question was: 'If you were to spend the rest of your life with your urinary condition the way it is now, how would you feel about that?' The possible answers to this question ranged from 'delighted' (a score of '0') to 'terrible' (a score of '6').","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.46","spread":"1.43"},{"groupId":"OG001","value":"-0.56","spread":"1.30"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.83","spread":"1.62"},{"groupId":"OG001","value":"-0.79","spread":"1.37"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.99","spread":"1.64"},{"groupId":"OG001","value":"-1.01","spread":"1.38"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Burden of Urinary Symptoms Based on the Benign Prostatic Hyperplasia Impact Index (BPHII)","description":"The Benign Prostatic Hyperplasia Impact Index (BPHII) is a self-administered questionnaire to measure how much urinary problems affect various domains of health. The higher value the worse are the urinary problems. The minimum possible total value is 0 and the maximum possible total value is 16.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.78","spread":"2.03"},{"groupId":"OG001","value":"-0.70","spread":"2.34"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.88","spread":"2.73"},{"groupId":"OG001","value":"-1.09","spread":"2.48"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.28","spread":"2.62"},{"groupId":"OG001","value":"-1.16","spread":"2.67"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Markedly Abnormal Values in Vital Signs and Body Weight","description":"This outcome measure included incidence of markedly abnormal changes in blood pressure (systolic and diastolic), pulse, and body weight. The table presents the number of participants with normal baseline and at least one post-baseline markedly abnormal value.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Markedly Abnormal Values in Safety Laboratory Variables","description":"The figures present the number of participants who had abnormal (defined as above upper limit of normal range (ULN)) levels of safety laboratory variables. Only the laboratory variables that had at least one percentage of participants in either group with abnormal value are presented, more variables were included in the study.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13","spread":null},{"groupId":"OG001","value":"16","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]}]},{"type":"PRIMARY","title":"Change From Baseline in Prostate Size Based on Trans Rectal Ultra Sound (TRUS) at Week 12 (Per Protocol Analysis Set)","description":"TRUS is a method of measuring the size of the prostate.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-37.3","spread":"16.8"},{"groupId":"OG001","value":"-39.0","spread":"18.4"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":84},"commonTop":["Hot flush","Injection site pain","Hyperhidrosis","Erectile dysfunction","Weight decreased"]}}}